Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2017-03-24 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
募集资金存放与实际使用情况的鉴证报告
Regulatory Filings Classification · 90% confidence The document text contains only references to omitted pictures and a note about scanning software, with no substantive content, financial data, or report information. The document length is very short (246 characters) and does not contain any report or announcement text. Given the lack of content, it does not fit any specific report category and defaults to Regulatory Filings (RNS) as a fallback category.
2017-03-24 Chinese
八届二十九次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed by the board of directors of Kunming Pharmaceutical Group Co., Ltd. It includes voting results on various proposals such as the 2016 annual president's work report, board work report, independent directors' report, audit and risk control committee report, financial statements, profit distribution plan, social responsibility report, internal control reports, appointment of auditors, related party transactions, credit guarantees, remuneration plans, and changes in board members and senior management. The document is dated March 25, 2017, and references the 2016 fiscal year. It is a formal announcement of board meeting decisions rather than the full reports themselves. The document also states that many reports are published on the Shanghai Stock Exchange website, indicating this document is a board meeting resolution announcement. The presence of voting results and board decisions on management and board member changes further supports classification as Board/Management Information (MANG). The document length (5877 characters) and content confirm it is not a full annual report or financial report but a board meeting resolution announcement with voting results on various management and governance matters.
2017-03-24 Chinese
中审众环关于北京华方科泰医药有限公司2016年度业绩承诺完成情况专项审核报告
Audit Report / Information Classification · 95% confidence The document is an audit report issued by a certified public accounting firm (中审众环会计师事务所) regarding the 2016 performance commitment completion status of Beijing Huafang Ketai Pharmaceutical Co., Ltd. It references the audit of financial data for the year 2016, including net profit figures and compliance with regulatory requirements under the China Securities Regulatory Commission's rules for major asset restructurings. The document contains an auditor's opinion, audit procedures, and financial data related to the performance commitment. It is not a full annual report but a standalone audit report focused on a specific matter (performance commitment completion). The document length is 3290 characters, which is relatively short but contains substantive audit content and financial data, so it is not merely an announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2016
2017-03-24 Chinese
关于昆药集团股份有限公司控股股东及其他关联方占用资金情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a special explanatory statement issued by an accounting firm (Union Power Certified Public Accountants) regarding the non-operating funds occupied and other related party fund transactions of Kunming Pharmaceutical Group Co., Ltd. for the year ended December 31, 2016. It references the audited financial statements for 2016 and includes a detailed summary table of related party fund usage and balances. The document is a standalone audit-related report focusing on related party transactions and compliance with regulatory requirements from the China Securities Regulatory Commission. It is not a full annual report, nor an earnings release or management discussion. It is not a mere announcement or certification but contains substantive audit findings and detailed financial data related to audit procedures on related party transactions. Therefore, it fits the category of an Audit Report / Information (AR). The document length is under 5,000 characters but contains detailed audit information and tables, not just a brief announcement or certification, so it is not an RPA or RNS. Confidence is high due to clear audit report characteristics and regulatory references. FY 2016
2017-03-24 Chinese
关于召开2016年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2016 Annual General Meeting (AGM) of Kunming Pharmaceutical Group Co., Ltd. It includes details such as the date, location, voting methods, agenda items to be discussed, and instructions for shareholders. The document does not contain financial statements or detailed financial analysis but rather logistical and procedural information about the AGM. It is not the annual report itself, nor is it a voting results announcement or proxy solicitation. Given the content and the nature of the document, it fits the category of AGM Information (AGM-R). The document length is 4162 characters, which is consistent with a detailed AGM notice rather than a full report.
2017-03-24 Chinese
2016年年度报告
Annual Report Classification · 100% confidence The document is titled "2016 年年度报告" which translates to "2016 Annual Report". It contains detailed financial data, company overview, business summary, management discussion and analysis, and audited financial statements. The presence of audit opinions, detailed financial metrics, and comprehensive company information confirms this is a full annual report. The document length is 15,000 characters, which is substantial and consistent with a full report rather than a brief announcement. There is no indication that this is merely an announcement or a certification. Therefore, the document fits the definition of an Annual Report (10-K). FY 2016
2017-03-24 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.